# Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

> **NCT04082416** · PHASE3 · COMPLETED · sponsor: **RemeGen Co., Ltd.** · enrollment: 335 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** Placebo plus standard therapy
- **BIOLOGICAL:** RC18 160 mg plus standard therapy

## Key facts

- **NCT ID:** NCT04082416
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-16
- **Primary completion:** 2022-04-24
- **Final completion:** 2022-06-30
- **Target enrollment:** 335 (ACTUAL)
- **Last updated:** 2023-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04082416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04082416, "Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04082416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*